Abstract
BackgroundTherapies that target TNF have been successfully used for the treatment of patients with rheumatoid arthritis (RA) and spondylarthropathies (SpA). TNF-α blocking agents have been relatively safe, however intravenous administration...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
